RCUS Arcus Biosciences Inc
Price (delayed)
$7.89
Market cap
$835.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.14
Enterprise value
$733.09M
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
Highlights
RCUS's revenue has soared by 121% YoY
The gross profit has soared by 121% YoY
RCUS's equity is down by 14% since the previous quarter but it is up by 5% year-on-year
RCUS's quick ratio is down by 14% since the previous quarter but it is up by 2.1% year-on-year
Arcus Biosciences's debt has increased by 2.1% from the previous quarter
Key stats
What are the main financial stats of RCUS
Market
Valuations
Earnings
Shares outstanding
105.84M
Market cap
$835.09M
Enterprise value
$733.09M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.49
Price to sales (P/S)
2.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.84
Revenue
$258M
Gross profit
$258M
Operating income
-$330M
Net income
-$283M
EBIT
-$278M
EBITDA
-$261M
Free cash flow
-$176M
Per share
Balance sheet
Liquidity
EPS
-$3.14
EPS diluted
-$3.14
Free cash flow per share
-$1.95
Book value per share
$5.3
Revenue per share
$2.86
TBVPS
$12.76
Total assets
$1.15B
Total liabilities
$665M
Debt
$48M
Equity
$485M
Working capital
$790M
Debt to equity
0.1
Current ratio
4.5
Quick ratio
4.42
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
-101.2%
Gross margin
100%
Net margin
-109.7%
Operating margin
-127.9%
Return on assets
-23.2%
Return on equity
-47.3%
Return on invested capital
-32.3%
Return on capital employed
-30.1%
Return on sales
-107.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RCUS stock price
How has the Arcus Biosciences stock price performed over time
Intraday
2.33%
1 week
-4.48%
1 month
-27.55%
1 year
-55.47%
YTD
-47.01%
QTD
0.51%
Financial performance
How have Arcus Biosciences's revenue and profit performed over time
Revenue
$258M
Gross profit
$258M
Operating income
-$330M
Net income
-$283M
Gross margin
100%
Net margin
-109.7%
RCUS's revenue has soared by 121% YoY
The gross profit has soared by 121% YoY
Arcus Biosciences's net margin has soared by 58% YoY but it has decreased by 7% from the previous quarter
The operating margin has surged by 56% year-on-year but it has declined by 6% since the previous quarter
Growth
What is Arcus Biosciences's growth rate over time
Valuation
What is Arcus Biosciences stock price valuation
P/E
N/A
P/B
1.49
P/S
2.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.84
RCUS's EPS is up by 24% year-on-year
RCUS's price to book (P/B) is 48% lower than its 5-year quarterly average of 2.8 and 42% lower than its last 4 quarters average of 2.5
RCUS's equity is down by 14% since the previous quarter but it is up by 5% year-on-year
RCUS's revenue has soared by 121% YoY
RCUS's P/S is 84% below its 5-year quarterly average of 17.0 and 54% below its last 4 quarters average of 5.8
Efficiency
How efficient is Arcus Biosciences business performance
RCUS's return on sales has surged by 58% year-on-year but it is down by 6% since the previous quarter
The return on equity has increased by 17% year-on-year but it has declined by 3.7% since the previous quarter
RCUS's ROIC is up by 12% YoY but it is down by 2.5% from the previous quarter
Arcus Biosciences's return on assets has increased by 10% YoY but it has decreased by 3.6% QoQ
Dividends
What is RCUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RCUS.
Financial health
How did Arcus Biosciences financials performed over time
The total assets is 73% greater than the total liabilities
RCUS's quick ratio is down by 14% since the previous quarter but it is up by 2.1% year-on-year
RCUS's current ratio is down by 14% from the previous quarter
Arcus Biosciences's debt is 90% less than its equity
RCUS's debt to equity is up by 25% since the previous quarter
RCUS's equity is down by 14% since the previous quarter but it is up by 5% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.